Roth Capital Doubles PT on Keryx (KERX); Sees Another 200% Upside
Tweet Send to a Friend
Roth Capital's Joseph Pantginis boosted his price target on Keryx Biopharmaceuticals (NASDAQ: KERX) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE